Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France.

Huguet M, Perrier L, Bally O, Benayoun D, De Saint Hilaire P, Beal Ardisson D, Morelle M, Havet N, Joutard X, Meeus P, Gabelle P, Provençal J, Chauleur C, Glehen O, Charreton A, Farsi F, Ray-Coquard I.

BMC Health Serv Res. 2018 Jan 4;18(1):3. doi: 10.1186/s12913-017-2802-2.

2.

[Orbital inflammatory pseudotumor secondary to sarcoidosis].

Brunelle C, Bally S, Provencal J, Lecomte C.

J Fr Ophtalmol. 2016 Sep;39(7):e179-81. doi: 10.1016/j.jfo.2015.07.017. Epub 2016 Aug 17. French. No abstract available.

3.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, Gasmi M, Locher C, Adhoute X, Michel P, Khemissa F, Lecomte T, Provençal J, Breysacher G, Legoux JL, Lepère C, Charneau J, Cretin J, Chone L, Azzedine A, Bouché O, Sobhani I, Bedenne L, Mitry E; FFCD investigators.

Ann Oncol. 2016 Jan;27(1):121-7. doi: 10.1093/annonc/mdv491. Epub 2015 Oct 20.

PMID:
26487578
4.

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Pérol D, Provençal J, Hardy-Bessard AC, Coeffic D, Jacquin JP, Agostini C, Bachelot T, Guastalla JP, Pivot X, Martin JP, Bajard A, Ray-Coquard I.

BMC Cancer. 2012 Dec 17;12:603. doi: 10.1186/1471-2407-12-603.

5.

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.

Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K.

Eur J Cancer. 2012 Mar;48(5):721-7. doi: 10.1016/j.ejca.2012.01.011. Epub 2012 Feb 6. Review.

PMID:
22317952
6.

Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.

Bachelot T, Bajard A, Ray-Coquard I, Provencal J, Coeffic D, Agostini C, Boisseau M, Kaphan R, Dramais D, Oprea C, Ferri-Dessens RM, Guastalla JP, Perol D.

Oncology. 2011;80(3-4):262-8. doi: 10.1159/000329066. Epub 2011 Jul 6.

PMID:
21734418
7.

Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients.

Ray-Coquard I, Weber B, Lotz JP, Tournigand C, Provencal J, Mayeur D, Treilleux I, Paraiso D, Duvillard P, Pujade-Lauraine E; GINECO group.

Gynecol Oncol. 2010 Oct;119(1):53-9. doi: 10.1016/j.ygyno.2010.05.023. Epub 2010 Jun 30.

PMID:
20580063
8.

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.

Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Lévy E, Hardy-Bessard AC, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H, Agostini C, Provencal J, Ferrero JM, Fric D, Dohollou N, Paraiso D, Salvat J, Pujade-Lauraine E; GINECO group.

Br J Cancer. 2009 Feb 24;100(4):601-7. doi: 10.1038/sj.bjc.6604878. Epub 2009 Feb 3.

9.

Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

Trédan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E, Freyer G; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

Ann Oncol. 2007 Feb;18(2):256-62. Epub 2006 Nov 2.

PMID:
17082510
10.

Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.

Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E.

Ann Oncol. 2005 Nov;16(11):1795-800. Epub 2005 Aug 10.

PMID:
16093275
11.

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

Bécouarn Y, Gamelin E, Coudert B, Négrier S, Pierga JY, Raoul JL, Provençal J, Rixe O, Krisch C, Germa C, Bekradda M, Mignard D, Mousseau M.

J Clin Oncol. 2001 Nov 15;19(22):4195-201.

PMID:
11709562
13.

NMR assignments and secondary structure of the retinoid X receptor alpha DNA-binding domain. Evidence for the novel C-terminal helix.

Lee MS, Sem DS, Kliewer SA, Provencal J, Evans RM, Wright PE.

Eur J Biochem. 1994 Sep 1;224(2):639-50.

14.

Structure of the retinoid X receptor alpha DNA binding domain: a helix required for homodimeric DNA binding.

Lee MS, Kliewer SA, Provencal J, Wright PE, Evans RM.

Science. 1993 May 21;260(5111):1117-21.

PMID:
8388124

Supplemental Content

Loading ...
Support Center